MelaGenix – the new multigene expression test
The prognostic eight-gene signature of MelaGenix is the result of 20 years of scientific research. The activity pattern of these genes provides the resultant MelaGenix risk score (MG score) that supplements your current prognostic assessment and can fundamentally change treatment decisions , based on significant changes in the overall survival probability (Fig. 1). The MelaGenix multigene expression test was developed to determine the risk of relapse of patients who are diagnosed with melanoma in the early and intermediate stages (AJCC stages I and II) and for the treatment optimization for patients who already display regional metastasis at the time of diagnosis (AJCC stage III).
The MelaGenix score determines the individual risk of relapse. It can result in an entirely new assessment of melanoma outcome for many patients and, thus, can significantly change treatment decisions in melanoma care